Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$8.92 0.39 (4.19%) as of 4:30 Tue 4/23


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 97,871,000
Market Cap: 873.01(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.66 - $22.03
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 20.2
Insider 6 Months    : 20.2
Insider 3/6 Months : 40.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,350,000 1,350,000 1,350,000 7,872,717
Total Buy Value $20,722,500 $20,722,500 $20,722,500 $80,714,496
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 6
Total Shares Sold 57,195 107,195 154,628 206,908
Total Sell Value $623,326 $1,183,326 $2,078,063 $2,842,845
Total People Sold 1 1 4 5
Total Sell Transactions 2 3 7 15
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 190
  Page 1 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Shah Rajeev M. Director   –       •       •   2024-04-11 4 OE $5.33 $7,499,996 I/I 1,408,450 13,840,034     -
   Palekar Rohan Chief Executive Officer   •       •      –    2024-04-01 4 AS $10.91 $575,153 D/D (52,718) 459,171 -15%     
   Palekar Rohan Chief Executive Officer   •       •      –    2024-04-01 4 OE $1.93 $48,250 D/D 25,000 511,889     -
   Shah Rajeev M. Director   –       •       •   2024-03-04 4 B $15.35 $20,722,500 I/I 1,350,000 12,431,584 2.25 -34%     
   Palekar Rohan Chief Executive Officer   •       •      –    2024-02-26 4 AS $10.76 $48,173 D/D (4,477) 486,889 -18%     
   Martins Ryan Chief Financial Officer   •       –      –    2024-02-17 4 D $9.74 $7,578 D/D (778) 106,609     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2024-02-17 4 D $9.74 $10,188 D/D (1,046) 158,437     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-02-17 4 D $9.74 $10,188 D/D (1,046) 222,149     -
   Palekar Rohan Chief Executive Officer   •       •      –    2024-02-17 4 D $9.74 $44,823 D/D (4,602) 491,366     -
   Martins Ryan Chief Financial Officer   •       –      –    2024-02-09 4 D $8.45 $30,150 D/D (3,568) 107,387     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2024-02-09 4 D $8.45 $30,150 D/D (3,568) 159,483     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-02-09 4 D $8.45 $30,150 D/D (3,568) 223,195     -
   Palekar Rohan Chief Executive Officer   •       •      –    2024-02-09 4 D $8.45 $107,062 D/D (12,670) 480,968     -
   Palekar Rohan Chief Executive Officer   •       •      –    2024-02-05 4 D $9.80 $49,666 D/D (5,068) 493,646     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-02-05 4 D $9.80 $11,662 D/D (1,190) 226,763     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2024-02-05 4 D $9.80 $11,662 D/D (1,190) 163,051     -
   Martins Ryan Chief Financial Officer   •       –      –    2024-02-05 4 D $9.80 $8,742 D/D (892) 110,955     -
   Palekar Rohan Chief Executive Officer   •       •      –    2024-02-01 4 A $0.00 $0 D/D 150,000 498,714     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-02-01 4 A $0.00 $0 D/D 48,750 227,953     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 48,750 164,241     -
   Martins Ryan Chief Financial Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 48,750 111,847     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-01-05 4 D $11.53 $111,507 D/D (9,671) 179,203     -
   Le-Nguyen Quoc See Remarks   •       –      –    2024-01-05 4 A $0.00 $0 D/D 25,000 188,874     -
   Martins Ryan Chief Financial Officer   •       –      –    2024-01-05 4 D $11.53 $70,610 D/D (6,124) 63,097     -
   Martins Ryan Chief Financial Officer   •       –      –    2024-01-05 4 A $0.00 $0 D/D 15,000 69,221     -
  190 Records found
  1  2  3  4  5  6  7  8   
  Page 1 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us